Uscom (UCM.AX) Aktsia Kursus

Uscom Kursus

ASX·SULETUD
0,01
​
Turg suletud

Viimase 19 aasta jooksul kasvas Uscom käive 4,5 % aastas ja jõudis 2,58 M AUD-ni. Uscom netomarginaal −128,1 % on langenud võrreldes −24,0 %-ga mõni aasta tagasi.

Uscom aktsiahinnad

Hangi need andmed Eulerpool API kaudu

100 000 päringut/kuus tasuta · krediitkaarti pole

Uscom ärimudel ja aktsia analüüs

Uscom Ltd on Austraalia ettevõte, mis asutati 2000. aastal. Ettevõte keskendub meditsiiniseadmete ja -seadmete arendamisele, tootmisele ning turustamisele, rõhutades kardiovaskulaarset diagnostikat. Ettevõtte peakontort asub Sydney'is, Austraalias, ja sellel on filiaalid Euroopas, Põhja-Ameerikas ja Aasias. Uscomi meeskonda kuuluvad kogenud teadlased, insenerid ja meditsiinitöötajad, kes koostööd tehes toodavad ja pakuvad kõrge kvaliteediga tooteid, mida tunnustatakse ülemaailmselt meditsiinivaldkonnas. Uscomi ärimudel põhineb innovaatiliste seadmete arendamisel, mis aitavad arstidel ja meditsiinitöötajatel oma patsiente tõhusamalt diagnoosida ja ravida. Aastate jooksul on ettevõte oma portfellii mitmekesistanud ja pakub nüüd erinevatesse kategooriatesse liigitatavaid tooteid. Üks Uscomi peamisi osakondi on ultrahelisignaalide seadmete tootmine, mida saab kasutada verevoolu, vererõhu ja muude oluliste kardiovaskulaarsete parameetrite mõõtmiseks. Need seadmed on eriti kasulikud hüpertensiooni, südamepuudulikkuse ja insuldi sarnaste kardiovaskulaarhaigustega patsientide diagnoosimisel ja jälgimisel. Uscom pakub ka spetsiaalselt intensiivravi- ja kiirabiosakondade jaoks mõeldud seadmete valikut. Nende hulka kuuluvad mittetinvasiivsed vererõhumõõturid, ventilatsiooniseadmed ja jälgimissüsteemid, mis võimaldavad patsientide kiiret ja täpset jälgimist. Neid seadmeid kasutavad meditsiinitöötajad üle maailma elude päästmiseks ja kriitiliste haiguste ravi parandamiseks. Lisaks meditsiiniseadmetele pakub Uscom ka erinevaid koolitus- ja täiendkoolitusprogramme meditsiinitöötajatele. Need koolitused hõlmavad kursusi seadmete kasutamise kohta ning üldisi koolitusi kardiovaskulaarse tervise ja diagnostika alal. Viimasel ajal on Uscom spetsialiseerunud telemeditsiini lahenduste arendamisele ja turustamisele. Need lahendused võimaldavad arstidel ja patsientidel vahetada teavet kaugelt. See on eriti kasulik kaugaladel asuvate patsientide hooldamisel ja teistes olukordades, kus juurdepääs meditsiinitöötajatele on piiratud. Üks Uscomi hiljutisi arendusi on kaasaskantav ultraheli Doppleri seade, mida saab kasutada verevoolu, löögimahu ja muude oluliste kardiovaskulaarsete parameetrite mõõtmiseks. See seade on kerge ja lihtne kasutada, võimaldades arstidel patsiente kiiresti ja täpselt diagnoosida igas kliinilises keskkonnas. Kokkuvõtteks on Uscom loonud hea maine meditsiiniettevõtluses ja teda peetakse juhtivaks ettevõtteks kardiovaskulaarses diagnostikas. Ettevõte jätkab pingutusi innovaatiliste toodete ja lahenduste arendamiseks, mis saavad parandada patsientide elu üle maailma.

Korduma kippuvad küsimused Uscom aktsia kohta

The main competitors of Uscom Ltd in the market include global medical device companies such as Edwards Lifesciences Corporation, Masimo Corporation, and Nonin Medical Inc. These companies also specialize in developing and manufacturing medical devices and technologies, particularly focused on cardiovascular care and continuous non-invasive monitoring. Uscom Ltd competes with these industry leaders by offering unique and innovative products, such as its non-invasive hemodynamic monitoring systems. As Uscom Ltd continues to expand its market presence and enhance its product offerings, it aims to effectively compete with these key players in the medical device market.

The business model of Uscom Ltd is centered around the development and commercialization of non-invasive medical devices for the assessment of cardiovascular and pulmonary function. Uscom specializes in the manufacturing of innovative devices that provide accurate and reliable measurements of various hemodynamic parameters. Their products, such as the Uscom 1A, are designed to assist healthcare professionals in diagnosing and managing cardiovascular conditions. By leveraging their expertise in medical technology and continuous innovation, Uscom aims to improve patient outcomes and enhance the efficiency of medical care in cardiology and other related fields.

Uscom Ltd is primarily active in the medical device industry.

Uscom Ltd, headquartered in Sydney, Australia, is a medical device company specializing in non-invasive cardiovascular and pulmonary monitoring equipment. Established in 2000, the company has a rich history in developing innovative medical technologies. Uscom's flagship product, the Uscom 1A, is a non-invasive, portable device that provides real-time measurements of cardiac output, blood pressure, and other vital cardiovascular parameters. With a global presence, Uscom has achieved remarkable success in the medical industry by offering advanced medical solutions. Combining cutting-edge technology and clinical expertise, Uscom continues to lead the way in non-invasive monitoring for the advancement of patient care worldwide.

Uscom Ltd has achieved several significant milestones in its journey. The company has successfully developed and patented non-invasive cardiovascular monitoring technologies, such as the USCOM 1A device. Uscom's USCOM 1A has been internationally recognized and adopted by healthcare professionals for its accuracy in measuring hemodynamic parameters. Uscom Ltd has also expanded its presence globally, with distribution agreements established in various countries. Furthermore, the company has received regulatory approvals, such as the CE Mark and clearance from the US FDA, enabling it to provide its innovative solutions to a wider market. Uscom Ltd continues to pave the way for advancements in cardiovascular monitoring technology.

Uscom Ltd is primarily present in Australia and the Asia-Pacific region.

Uscom Ltd represents values of innovation, excellence, and integrity. With a strong corporate philosophy focused on delivering advanced medical devices, Uscom Ltd is committed to improving patient outcomes and revolutionizing diagnostic solutions. With a passion for research and development, the company aims to provide cutting-edge technology in the field of cardiovascular health. Uscom Ltd's dedication to quality and accuracy sets them apart, ensuring healthcare professionals have access to accurate diagnostic tools for optimal patient care. By embodying these values, Uscom Ltd continues to make significant contributions to the healthcare industry.

Praeguse kursiga kaubeldakse Uscom aktsiaga 0,01 EUR (0,01 AUD) juures.

Uscom aktsia (UCM.AX) on noteeritud 1 börsil, sh: ASX (UCM.AX).

Uscom Ltd is an Australian medical technology company specializing in non-invasive cardiovascular diagnostics. The company's business model is based on the development, manufacture, and sale of innovative medical devices and solutions that enable more precise and effective diagnosis and monitoring of heart diseases. Uscom is divided into two main divisions: clinical diagnostics and telemedical monitoring. In the clinical diagnostics division, Uscom offers the Doppler hemodynamic systems USCOM 1A and USCOM SpiroFlo for assessing hemodynamics in clinical settings. These devices are popular at leading medical institutions worldwide due to their high accuracy and user-friendliness. In the telemedical monitoring division, Uscom offers the USCOM BP+, a portable wireless blood pressure monitor that allows measurement and monitoring of blood pressure in non-clinical settings. With the USCOM BP+, doctors and nurses can monitor patients' blood pressure in real-time and ensure more accurate treatment. Uscom also produces a range of software solutions that enable seamless integration of USCOM devices into the medical infrastructure of hospitals and clinics. The USCOM CMS software (Cardiovascular Management System) is a web-based solution for managing patient data and generating reports. The USCOM SPIRO software enables integration of clinical spirometers into the USCOM system, providing a comprehensive solution for assessing patients' cardiorespiratory health. Uscom Ltd also grants licensing agreements to partner companies to distribute USCOM devices and solutions in specific regions or market segments. Currently, Uscom has licensing agreements in North America, Europe, Asia, and Australia. Uscom Ltd's business model is based on providing high-quality and innovative medical devices and solutions that enhance the accuracy and effectiveness of cardiovascular diagnosis and monitoring. The company works closely with leading medical professionals and institutions to ensure its products meet the highest standards. With a strong focus on research and development and a global presence, Uscom Ltd aims to be the preferred partner for medical professionals and institutions that require the most accurate and effective assessment of patients' cardiovascular health.

Käivet ei saa praegu Uscom kohta arvutada.

Kasumit ei saa praegu Uscom kohta arvutada.

P/E-suhtarvu ei saa praegu Uscom kohta arvutada.

P/S-suhtarvu ei saa praegu Uscom kohta arvutada.

Eulpooli kvaliteedinäitaja Uscom jaoks on 2/10.

Uscom ISIN on AU000000UCM2. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.

Uscom WKN on A0B7BV. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.

Uscom ticker on UCM.AX. Ticker-sümbol kasutatakse Uscom aktsiate kauplemiseks börsil.

Õiglane väärtusTerminal
0,01 AUD
Üle-/alahinnangTerminal
Õiglaselt hinnatakse
Tööstus
Tervishoiuvarustus ja tarvikud
Aktsiate arv
Töötajad
Tulu töötaja kohta
234 435,73 AUD
Tulukasvu keskmine 5 aastat
EBIT kasvu keskmine 5 aastat
Puhaskasumi kasvu keskmine 5 aastat
Veebisait uscom.com.au
Riik
Austraalia
Valuuta
AUD
Börsi noteerimise algus
10. dets 2003
ISIN
AU000000UCM2
CUSIP
Q93295105
SEDOL
6717553
Turukapitalisatsioon
3,12 M AUDMicro Cap
52-nädala vahemik
PEG
—
P/E suhe
P/E e
—
P/S
P/S e
—
EV/EBIT
—
P/B suhe
1,02
ROE (omakapitali tootlus)
ROA (varatootlus)
ROCE (kasutatud kapitali tootlus)
ROIC (investeeritud kapitali tootlus)
−148,40 %
Viimati värskendatud 16. okt 2026, 22:28

Uscom Börsiticker

ASX · UCM.AX

Uscom FIGI

UCM:AU · BBG000BC9ZV9UCM:AT · BBG000BCB0J7UCM:AH · BBG002F3FGX4

Kõik teised näitajad ja analüüsid Uscom kohta sügavamalt

Meie Uscom-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Uscom. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: